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 Patient-centered management of actinic keratosis. Results of a multi-center 
clinical consensus analyzing non-melanoma skin cancer patient profiles and 
field-treatment strategies  
Abstract 
Introduction: Actinic keratosis (AK) is a chronic skin condition that can be a 
precursor to cutaneous squamous cell carcinoma. AK can recur and patients are likely 
to undergo multiple treatments. It is important that AK lesions are managed 
appropriately, and that patients are involved in treatment decisions.  
Materials and methods: The Supporting Professional Expertise in AK (SPEAK) 
program aims to facilitate this patient-centered care by identifying patient needs and 
aiding healthcare practitioners (HCPs) in selecting optimal treatment and 
communication strategies for different types of patients. Twenty-two dermato-
oncologists with established expertise in the treatment of AK collaborated to describe 
commonly encountered psychosocial patient profiles, and to develop respective 
communication and treatment strategies.  
Results and conclusion: Six patient profiles were defined based on different 
psychosocial characteristics and were used to develop appropriate management 
approaches. We provide a systematic way of identifying these patient profiles in 
clinical practice and we outline communication strategies tailored to the primary needs 
of each type of patient. In addition, we provide recommendations for potential field-
treatments that may be best suited for each profile. The recommendations provided here 
may help improve the communication and relationship between patients and HCPs, 
resulting in higher treatment adherence and improved patient outcomes.  
Keywords: actinic keratosis, cutaneous squamous cell carcinoma, management 
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 Introduction 
Actinic keratosis (AK), a chronic skin condition caused predominately by prolonged exposure 
to ultraviolet (UV) radiation, is a precursor to cutaneous squamous cell carcinoma (SCC). 
Estimates range from 0.1–10% of AK progressing to SCC [1,2]; in addition, approximately 
97% of cutaneous SCCs are contiguous to an AK [3], which may represent carcinoma in situ 
[4].  
Whilst many AK lesions resolve spontaneously, some can be potentially invasive, 
regardless of their intra-epidermal thickness [2,5], and it is not possible to draw conclusions 
about the histology of AK lesions from their clinical appearance [6]. For this reason, coupled 
with a lack of supporting long-term prognostic studies, it is important that AK lesions are 
managed appropriately[2]. Appropriate management of AK can be in the form of lesion-
specific or field-directed therapy. Visible AK lesions can arise from subclinical changes that 
affect a wider area of skin, a process known as cancerization,[3,7] in these instances a field-
directed therapy may be advantageous allowing effective treatment of sub-clinical AK lesions 
that may be missed with lesion-specific therapy. Moreover, current studies have highlighted, 
that the potential to develop squamous cell carcinomas is associated with subclinical basal 
proliferating AKs as well as clinical hyperkeratotic AKs, indicating a need for standardized, 
and approved field therapy[8,9]When deciding on a management strategy it is important to 
consider a multitude of factors, including treatment duration, compliance, cost and risk 
factors for recurrence and the age of the patient.[2]  
 In addition, patients increasingly expect to be involved in decision-making about 
treatments, especially as AK can recur and people with AK are likely to need multiple 
treatment courses throughout their lifetime. [10] Therefore, a practical tool that takes into 
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 account patient-related factors may be particularly useful for assisting doctors in optimizing 
the efficiency of their consultations. 
Indeed, patient-centric care is now a widely accepted part of high-quality healthcare in 
general, and seems to improve outcomes, quality of life, satisfaction and treatment adherence. 
Patient-centric care may also aid the adoption of patient-defined treatment goals and 
outcomes, [11] and in turn, help manage expectations.  
Based on this, the Supporting Professional Expertise in AK (SPEAK) program aims to 
facilitate patient-centric care in AK management, focusing on ways to appropriately identify 
the needs of different patients, and aid the physicians in selecting the best field-directed 
therapy for each patient in an effective and efficient way. The patient profiles and 
communication strategies developed in the program are outlined in this article and treatment 
recommendations for different patient profiles are discussed.  
Materials and methods 
In total, 22 dermatologists with expertise in the management of AK participated in a two-
stage process, across four meetings, to develop these clinical profiles and recommendations.  
Prerequisite conditions for expert involvement in the multi-center consensus analysis 
were specialization in dermato-oncology; consistent, long-term clinical treatment experience 
with non-melanoma skin cancer (NMSC) patients; and sole therapeutic responsibly within a 
certified skin cancer center. All participating experts met the conditions for inclusion. 
In the first stage, consensus meetings were held in Frankfurt, Germany; Paris, France; 
and Rome, Italy. Discussions were facilitated in the local language, and patient profiles were 
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 developed based on typical patient types commonly encountered by the participating experts 
in their clinical practice.  
During the second stage, six practicing experts represented the national consensus 
meetings by attending a final meeting in London, United Kingdom, to consolidate the patient 
profiles developed at a national level. Based on these profiles, the experts developed 
recommendations for the clinical management and optimal communication approach for each 
patient type in two smaller groups. Recommendations were discussed within the six-member 
group and agreed by consensus, after which the experts discussed each of the patient profiles 
individually and adjusted the recommendations until a unanimous agreement was met.  
Therefore, the recommendations in this document represent the expert consensus 
opinion regarding strategies and techniques that can guide the individualization of AK 
management. Nevertheless, the experts recognize that each healthcare practitioner (HCP) 
needs to precisely tailor treatment and communication to each individual patient.   
Results  
Recommendations 
This section includes the characteristics of each patient profile (as defined by clinical 
experts); questions that can be used to identify each patient profile in clinical practice; and 
management priorities as well as treatment recommendations for each patient profile. 
We summarized the main attributes of six patient profiles (Table 1). An individual 
patient may not fit exactly into any one particular profile and some people with AK may have 
characteristics custom of more than one profile: e.g. an academic biologist, geologist or 
archaeologist working in the field may develop occupational AK. Nevertheless, the profiles 
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 offer a heuristic method to identify an appropriate management approach and consultation 
style that can guide discussions about AK and facilitate the optimal approach to treatment. 
For instance, a patient who is anxious about the diagnosis or treatment may benefit from 
reassurance about the likelihood of malignant transformation, or the systemic effects and 
safety of treatment, respectively. 
AK is typically diagnosed on clinical grounds, [10] so taking a detailed patient history 
is mandatory prior to identifying the profile category a patient best identifies with; 
determined using answers to a questionnaire (Table 2). For instance, the concerns and needs 
of the patients identified can be linked to the appropriate anxious or concerned profile groups, 
whereas their knowledge and level of engagement can also provide useful insight to 
categorizing them into the right profile. 
It should be noted that immunocompromised patients, who may be at risk of diffuse 
AK and may be receiving immunosuppressive therapies, can display any of the proposed 
profiles. When evaluating the communication and treatment strategy for these patients, it is 
important to consider both the type of profile describing each patient and also the fact that 
they present with immunosuppression. Therefore, these patients may also need to be treated 
at multiple areas simultaneously and may require additional therapies for the management of 
severe local skin reactions.   
[INSERT TABLE 1 HERE] 
[INSERT TABLE 2 HERE] 
Toward patient-centered AK management 
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 This section details how the identified patient profiles can be used to deliver patient-centric 
management of AK, where the relationship between patient and HCP is built on effective 
communication, empathy and a feeling of partnership. [12]  
Against this background, we outline recommended management priorities and 
potential treatments to consider for each of the patient profiles (Table 3). For example, in the 
panel’s experience, people who developed AK following occupational exposure need a fast, 
effective regimen with a short duration of treatment, especially as their potentially low 
engagement with the disease could translate into poor adherence.  
The panel recommends adapting HCP communication style to meet the primary needs 
of each patient profile (Table 4). For example, HCPs may need to reassure people who are 
concerned about the cosmetic outcomes that short-term skin reactions, which are common 
with topical treatments, do not influence long-term aesthetic outcomes and are a result of the 
treatment being effective, rather than simply being a side effect accompanying the treatment. 
Using appropriate terminology when speaking to patients 
To deliver education within a patient-centric framework, we recommend HCPs ensure that 
discussions about AK build on each patient’s existing knowledge and reflect their 
expectations and concerns. This means using appropriate terminology and establishing the 
introductory terminology, such as explaining the chronic nature of AK. Moreover, the 
terminology used during a discussion of the same topic could differ markedly for people who 
develop AK following occupational exposure, and for those patients who are more 
knowledgeable, reflecting their different levels of health literacy. 
An important communication goal is to ensure patients understand the normal role of 
local skin reactions in AK treatment, and that they appreciate them as a positive indication of 
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 the treatment’s function. We advise that HCPs aim to help patients become familiar with any 
management approaches that might reduce the severity of local reactions and educate patients 
on when to seek further assistance. Prescribing treatments such as photodynamic therapy 
(PDT) or ingenol mebutate that have well-characterized and predictable reactions may 
simplify these discussions. 
[INSERT TABLE 3 HERE] 
[INSERT TABLE 4 HERE] 
[INSERT TABLE 5 HERE] 
General treatment recommendations 
The panel identified which treatments may be recommended for different patients based on 
their individual profile and characteristics (Table 5). For instance, these recommendations 
take into account which therapies may be associated with unpredictable local skin reactions 
or variable outcomes compared with good aesthetic long-term outcomes, and how aspects of 
each therapy might be perceived by patients of different profiles.  
Practical recommendations for application of topical treatments 
HCPs should communicate clearly to patients the exact area over which they, or a carer (e.g. 
for inaccessible parts of the body), should apply a topical treatment.  
Alternatively, HCPs could provide patients who have smartphones with digital 
cameras, a photographic reference for the area being treated. A photographic reference can be 
particularly helpful for formulations with long treatment durations or if the HCP and patient 
agree to postpone the start of treatment.  
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 Educational brochures that provide skin maps; illustrations of the appearance of skin 
and lesions before, during and after treatment; as well as those showing local skin reactions, 
are available. Experts stress the importance of such detailed, up-to-date leaflets to provide 
patients with information about treatment options and facilitate their discussions with HCPs. 
Discussion 
The panel intends to raise awareness of the optimal management of AK, providing it as an 
educational resource, as well as helping HCPs implement local and national treatment 
guidelines in their daily clinical practice. The patient profiles and related recommendations in 
this document are intended as a pragmatic and heuristic guide to support patient management 
based on their main characteristics. 
In order to support the individualization of treatment for patients with AK, the present 
recommendations go beyond the treatment-focused, disease-driven framework typically used, 
[4,13] and take into account patient-related factors that are often neglected by guidelines and 
recommendations. [14] In particular, the educational messages about AK can be tailored 
according to each patient’s profile by using appropriate terminology that is adjusted to each 
patient’s educational background. This ‘consumerist’ model of interaction between patient 
and HCP is generally increasingly common in medicine. [15] Similarly, the suggested guide 
provides a patient-centric framework with recommendations to support optimal management 
and physician-patient communication in order to cultivate empathy and a feeling of 
partnership. [12,16] 
For many cases of AK, several treatment approaches are potentially suitable based on 
existing guidelines. This document therefore further complements existing guidelines and 
previous consensus papers by providing recommendations about selecting the appropriate 
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 treatment based on the psychosocial needs of different patient profiles and counselling 
patients about appropriate use. 
Ingenol mebutate was one of the treatment options proposed for many of the profiles 
and this was driven by its association with good cosmetic outcomes [17,18]; the predictable 
nature of the treatment and related short-term local skin reactions [19–22]; and the fact that the 
administration regimen of ingenol mebutate allows for flexible use, as patients are able to 
decide how and when it is used according to their needs and individual condition. In a 
randomized, evaluator-blinded trial of ingenol mebutate 0.015% gel and diclofenac sodium 
3% gel, patients experienced a shorter duration of skin reactions, with a peak after one week, 
with ingenol mebutate compared with diclofenac sodium, who experienced reactions 
throughout the 90-day treatment. [3] These attributes support ingenol mebutate, in the panel’s 
opinion, as a viable option for many of the patient profiles; assuming its use is complemented 
by treatment-focused education delivered at treatment initiation. [23] Despite the presence of 
local skin reactions, a study of 274 patients using ingenol mebutate reported that 98.2% of 
patients were adherent to the 3-day administration regimen. [24] Collectively, this evidence 
supports the panel’s recommendation that ingenol mebutate therapy in patients that are well-
educated by their dermatologist can lead to consistent, standardized and effective outcomes, 
with predictable, short-term local skin reactions. 
In addition to ingenol mebutate, conventional photodynamic therapy (PDT) was also 
identified as a viable option for a number of patient profiles, particularly for patients that may 
be concerned with cosmetic outcomes during or after treatment. The quality of the cosmetic 
outcomes associated with PDT [24–26] were identified as key drivers for choosing this therapy, 
as they might reassure and better satisfy patients who are particularly concerned about this. 
Indeed, PDT was also associated with the highest quality of life ratings, alongside ingenol 
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 mebutate, [14] Similarly, daylight PDT was also recommended, as it has comparable efficacy 
to conventional PDT for the resolution of AK in the face or scalp,
 
and has been shown to 
effectively treat AK lesions in a home-based setting. [27] Patients have also reported reduced 
pain and higher satisfaction with its convenience and outcomes compared with conventional 
PDT, [28–30] as well as compared with imiquimod. [31] Finally, although imiquimod may not be 
the treatment of choice for everyone due to the unpredictable onset of local skin reactions and 
the potential of systemic adverse events, it should be highlighted that imiquimod has high 
efficacy in reducing AK lesions [32–34] regardless of disease severity, [35] and has been 
associated with good long-term, post-treatment cosmetic outcomes. [31] Therefore, it could 
also be considered as a viable option for appropriate patients.   
Although commonly used, the panel does not recommend cryotherapy, as a lesion-directed 
treatment for the patient profiles discussed (Table 5), due to the potential for missing sub-
clinical lesions, scarring, highly variable short and long term outcomes based on experience, 
and the requirement for multiple rounds of treatment. 
In conclusion, there is a need for further research and comparative studies to facilitate 
the development of evidence-based guidelines that use objective criteria to stratify AK 
patients.  
In the meantime, the authors hope that a mutualistic, patient-centric relationship, [15] 
aided by the guide developed here will improve patient and HCP satisfaction with diagnosis 
and treatment outcomes. Such a relationship could potentially improve adherence and 
persistence with topical therapy for AK; avoid patients misinterpreting an unpleasant skin 
reaction during treatment; optimize the use of time during consultations and follow-up; and 
ultimately result in improved outcomes, safety and satisfaction.  
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 Table 1: Common AK patient profiles encountered in clinical practice 
Profile 1. Unengaged (low 
medical engagement) 
2. Cosmetic 
concerned 
during treatment  
3. Cosmetic 
concerned post-
treatment  
4. Knowledgeable 
(high medical 
engagement) 
5. 
Diagnosis-
anxious 
6. Safety-anxious 
Description Often occupational 
UV exposure 
Concerned with 
local skin 
reactions during 
treatment 
Concerned with 
permanent cosmetic 
outcomes post-
treatment  
Well-informed 
patient 
Anxious 
about 
malignant 
diagnosis 
Anxious about 
general and long-
term adverse 
effects of 
treatment  
Clinical 
characteristic 
Severe photodamage 
Field cancerization 
present 
Scalp involvement 
Trunk and dorsum of 
the hands involvement 
Male > female 
Older age 
Moderate, 
diffuse 
photodamage 
Facial 
involvement 
Female > male 
 
Mild to moderate, 
diffuse 
photodamage,  
sun exposure 
mainly in the past  
Facial involvement 
Female > male 
Younger 
Moderate 
photodamage 
Facial 
involvement 
Mild/early 
stage disease 
Facial 
involvement 
Moderate 
photodamage 
Facial 
involvement 
 
 
Psychosocial 
characteristics 
Employment possibly 
involves working 
outdoors 
Lower level of formal 
education 
Unconcerned about 
disease 
Employment 
involves 
interaction with 
others 
High 
occupational 
status and 
responsibility 
without 
allowance for 
work 
interruption due 
Employment 
involves interaction 
with others  
Exposed 
occupational 
position in face-to-
face relationships 
(particularly in the 
field of customer 
relationships) 
Willingness for 
downtime but not 
Highly educated 
Internet and 
research literate 
Well-informed 
about AK 
treatments 
Worried/hyp
er-concerned 
Tendency to 
be cancer-
phobic 
Regular 
engagement 
with 
healthcare 
High 
treatment 
motivation 
High level of 
social interaction 
Well-informed – 
able to use the 
internet 
 
Ac
ce
pte
d M
an
us
cri
pt
 to long 
downtime  
Well-educated 
and informed 
No other health 
conditions 
 
for poor cosmetic 
long-term outcomes 
Well-educated and 
informed  
Knowledge 
regarding UV and 
skin aging; already 
cautious with sun 
exposure 
No other health 
conditions 
Other 
observations 
May live far from 
hospital/practice 
 
In some localities, 
occupational nature of 
condition may be 
relevant for 
reimbursement 
Sun exposure 
may be 
associated with 
holidays or 
outdoor sports  
Potentially 
concerned with 
appearance and 
awareness of 
healthy skin 
conditions 
 
May be employed 
in academic or 
healthcare field 
 
May use the term 
‘actinic keratosis’ 
unprompted 
May have 
low concern 
with 
cosmetic 
outcome, 
focused on 
effectiveness 
 
Already 
likely to be 
using sun 
protection 
 
May present 
with printed 
information 
May need 
reassurance 
regarding 
absence of 
systemic effects 
of treatment and 
safety of products 
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 Table 2: Questions to support identification of patient profile 
Question Potential profile identification 
What is your main concern 
about your skin? 
Focus in response on cosmetic appearance during or after treatment 
may suggest cosmetic concerned profile 
Focus in response on skin cancer may suggest safety-anxious profile 
What’s your occupation? 
Do you/did you work 
outdoors? 
 
Outdoor work may suggest profile with low medical engagement 
Occupations involving high levels of personal interaction (service 
industry, sales, etc.) may suggest cosmetic concern or safety-anxious 
profiles 
Does your appearance 
matter in your job or daily 
life? 
Positive response may suggest cosmetic concerned or safety-anxious 
profile 
What do you expect from 
treatment? 
A focus on cosmetic outcomes may suggest cosmetic concerned 
profile 
A high level of detail in response may suggest knowledgeable or 
safety-anxious profile 
A focus on the potential for pain or discomfort may suggest a safety-
anxious profile 
Would you accept 
downtime during treatment? 
Using a term common in cosmetic treatment may help identify patients 
who match the cosmetic concerned profile 
Would you be bothered by 
short-term local skin 
reactions? Do you care 
about scarring or 
These questions may help distinguish between cosmetic concerned 
during and post-treatment profiles 
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 hyperpigmentation? 
What do you already know 
about AK and the 
treatments? 
A focus in response on the visual appearance of local skin reactions 
and treatment outcomes may suggest cosmetic concerned profile 
A high level of knowledge may suggest knowledgeable or diagnosis-
anxious profile 
A focus in response on the transformation of AK into SCC may 
suggest diagnosis-anxious profile 
 
Do you have any 
preferences for your 
treatment? 
A positive response may indicate knowledgeable profile   
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 Table 3: Suggested management priorities for commonly encountered AK patient profiles 
Profile  Unengaged  
(low 
medical 
engagement) 
Cosmetic 
concerned during 
treatment 
Cosmetic concerned 
post-treatment 
Knowledgeable 
(high medical 
engagement) 
Diagnosis-
anxious 
Safety-
anxious 
Primary 
need 
Rapid 
treatment 
Reassurance 
about limited 
nature of local 
skin reactions 
Reassurance about 
safety of outcomes 
Information Reassurance 
of treatment 
efficacy 
Reassurance 
of treatment 
safety 
Focus of 
treatment 
Fast, 
effective 
treatment 
with short 
duration 
 
Limited cosmetic 
impact during 
treatment; 
predictable  
downtime 
Limited cosmetic 
impact after treatment; 
predictable long-term 
outcome 
Evidence-
based approach 
Fast, 
effective 
treatment 
with rapid 
signs of 
efficacy  
Treatment 
decision 
driven by 
safety 
Additional 
management 
suggestions 
Early 
follow-up 
Need for 
guidance 
and 
motivation 
from 
physician 
Use pictures to 
educate about 
course of 
treatment and 
local skin 
reactions 
 
Consider early 
follow-up for 
reassurance on 
normal treatment 
Provide additional 
information about 
selected treatment 
safety and outcomes 
 
Emphasize 
photoprotection 
Provide 
supplementary 
information 
about treatment 
efficacy and 
safety to 
support 
treatment 
choices 
Close 
follow-up 
 
Provide 
additional 
education 
on the 
realistic risk 
of AK 
evolution  
Early follow-
up 
consultation 
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 reactions and 
outcomes 
Notes Low 
engagement 
with disease 
anticipated 
to lead to 
low 
treatment 
adherence 
and 
preventative 
measures 
Consider 
prescribing 
moisturizing and 
healing creams 
for cosmetic 
management of 
local skin 
reactions 
Consider prescribing 
moisturizing and 
healing creams for 
improvement of long-
term cosmetic 
outcome, including 
early proper  
photoprotection to 
prevent 
hyperpigmentation 
(not only for 
preventative but also 
for cosmetic reasons) 
 May be 
unconcerned 
about local 
skin 
reactions, 
‘no pain, no 
gain’ 
This patient 
may 
particularly 
benefit from 
easy, direct 
access to a 
nurse or 
dermatologist 
through a 
telephone 
hotline 
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 Table 4: Communication strategies for commonly encountered AK patient profiles
*
 
Profile  Unengaged  
(low medical 
engagement) 
Cosmetic 
concerned 
during treatment 
Cosmetic 
concerned 
post-
treatment 
Knowledgeable 
(high medical 
engagement) 
Diagnosis-
anxious 
Safety-
anxious 
 
Suggested 
communication 
style 
 
Simple and direct 
communication – 
avoid complex 
terminology or 
explanations 
 
Provide 
reassurance on 
predictability of 
local skin 
reactions and 
their resolution 
 
Provide 
reassurance 
about 
outcomes of 
treatment 
 
Medical and 
scientific style 
 
Simple and 
direct 
communication; 
reassuring 
 
Reassuring; 
provide 
confidence in 
the safety of 
therapy 
 
Communication 
strategy 
 
Focus on 
motivating the 
patient on the need 
for treatment now 
vs potential for 
surgery later 
 
 
Focus on 
dermatologist 
experience with 
treatments 
 
 
 
 
 
Reassure 
that intense 
local skin 
reactions do 
not 
negatively 
influence 
long-term 
outcomes 
 
 
Provide 
patients with 
data, including 
key statistics to 
support an 
evidence-based 
approach 
 
 
Provide 
objective 
evaluation on 
the risk of AK 
evolution 
 
Acknowledge 
anxiety and 
explore – 
‘What are 
you most 
concerned 
about?’ 
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Consider role of 
partner/family in 
communication 
 
 
Emphasize 
predictability of 
local skin 
reaction time 
course, if 
applicable for 
chosen 
treatment 
 
Explain 
importance of 
local skin 
reaction in 
response to 
treatment 
 
Potentially 
discuss data 
suggesting 
improvement 
in skin 
quality 
following 
treatment, if 
applicable 
for chosen 
treatment 
 
 
Important to 
explain all 
treatment 
options, with 
an evaluation 
of pros and 
cons 
 
Avoid over-
complex 
terminology 
which can 
heighten 
anxiety 
 
Stress efficacy 
of treatment 
 
Discuss 
management of 
a chronic 
condition 
 
Discuss long-
term benefits 
of treatment 
 
Reassure on 
lack of 
systemic 
effects, if 
applicable for 
chosen 
therapy 
 
Explain 
importance 
of local skin 
reactions in 
response to 
treatment  
 
*All communications should depend on and be tailored according to the chosen treatment  
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 Table 5:  Considerations for field-directed therapy* in commonly encountered AK patient 
profiles 
Profile type Description Recommended 
treatments  
(in alphabetical order) 
Rationale Treatments 
not 
recommended 
Rationale 
 
Cosmetic 
concerned 
during 
treatment 
 
Concerned 
with 
cosmetic 
effects 
during 
treatment 
 
 
Conventional/daylight 
PDT 
Ingenol mebutate 
 
Outcomes with noticeable but 
short, predictable duration of 
local skin reactions 
 
 
 
Imiquimod 
 
 
 
Unpredictable 
onset of local skin 
reactions 
 
 
 
Alternative: 
Diclofenac 
 
Not recommended due to 
unpredictable outcomes, but 
an option for patients who 
would potentially prefer 
milder but longer lasting local 
reactions 
 
 
 
 
 
 
Cosmetic 
concerned  
post-treatment 
 
Concerned 
with 
cosmetic 
outcomes of 
treatment 
 
Conventional/daylight 
PDT 
Ingenol mebutate 
 
Potential for cosmetic 
improvement of signs of 
photo-aging following 
treatment 
 
5-fluorouracil 
 
Use with caution, 
overuse can lead to 
severe blistering 
resulting in 
scarring 
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Diclofenac 
may not be 
appropriate as 
monotherapy 
in some 
cases, due to 
its limited 
efficacy 
compared 
with other 
options 
 
 
 
Diagnosis-
anxious 
 
Anxious 
about 
diagnosis 
 
Conventional/daylight 
PDT 
Ingenol mebutate 
Imiquimod 
 
Efficacy-driven treatment 
decision 
 
 
 
 
 
 
Conventional 
PDT 
 
 
 
Potential for pain  
 
Alternative where 
lesion-directed 
treatment is 
appropriate: 
Excision/shave 
 
Provides material for 
histopathology (for patient 
reassurance) 
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Safety-anxious 
 
Anxious 
about long-
term adverse 
effects of 
treatment  
 
Daylight PDT 
Ingenol mebutate 
 
 
 
Tolerability-driven treatment 
decision 
 
 
 
 
Imiquimod 
 
Systemic 
absorption with 
immunomodulation 
 
 
Alternative: 
Diclofenac 
 
 
Good tolerability, but reduced 
efficacy 
 
Diclofenac 
 
 
Adherence issues 
anticipated due to 
lack of selectivity 
 
Unengaged 
 
Occupational 
exposure 
 
Conventional PDT 
 
 
 
Physician-directed treatment, 
potentially office-based 
 
 
Imiquimod 
 
 
 
Adherence issues 
anticipated due to 
lack of selectivity 
  
Ingenol mebutate 
 
 
 
 
Short duration of treatment, 
licensed and approved for 
multiple locations (face and 
body) 
 
 
Knowledgeable 
 
Well-
informed 
 
Conventional/daylight 
PDT 
 
Support patient decision 
making with assessment of 
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 patient  Ingenol mebutate 
Imiquimod 
efficacy and safety of each 
treatment 
*The panel does not recommend cryotherapy for these patient profiles as a lesion-directed 
treatment due to the potential for missing sub-clinical lesions, scarring, highly variable short 
and long term outcomes based on experience, and the requirement for multiple rounds of 
treatment. 
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